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Abstract
Islet transplantation is an established therapy for selected type 1 diabetes (T1D) patients 
with severe hypoglycemic unawareness and glycemic liability despite of insulin treat-
ment. However, the donor organ is limited. Porcine islets are the best alternative source 
to overcome this limitation, and pig-to-nonhuman primate (NHP) naked islet xenotrans-
plantation studies are being performed worldwide. Several studies including our own 
have presented successful proof-of-concept results based on immunosuppression regi-
men including the anti-CD154 monoclonal antibody. Particularly, long-term control of 
diabetes by adult porcine islet transplantation has been demonstrated in five consecu-
tive monkeys, and the longest survival was ~1000 days after transplantation. Currently, 
pig-to-NHP islet xenotransplantation based on clinically applicable immunosuppression 
regimen is being pursued. In this chapter, we will describe all the procedures of pig-
to-NHP naked islet xenotransplantation: (1) the porcine islet isolation from designated 
pathogen-free (DPF) miniature pigs, (2) diabetes induction in monkeys, (3) transplan-
tation procedure via the portal vein, (4) immune monitoring comprising humoral and 
cellular immunity after porcine islet transplantation, and finally (5) liver biopsy and sub-
sequent immunohistochemical procedure in detail.
Keywords: porcine islet, nonhuman primate, transplantation, immune monitoring, 
biopsy
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1. Introduction
Diabetes, a serious disease and a fast-growing worldwide epidemic, has culminated in that 
nearly 9% of global population is afflicted [1]. Most patients suffer from type 2 diabetes 
(T2D) in which genetic predisposition and harmful environmental exposure will lead to 
β-cell dysfunction and peripheral insulin resistance [2]. About 5–10% of the patients are 
afflicted with T1D where autoimmunity toward pancreatic β-cells induces β-cell death, and 
thus regular exogenous insulin treatment is absolutely required for the daily life of the 
patients [3]. In late 1960s, the procedure yielding large numbers of islets from the rodents 
was established using a commercial collagenase [4] and its ductal injection, and islet trans-
plantation into the portal vein of diabetic animals could lead to recovery from experimental 
diabetes [5]. As islet isolation from large animals including the pigs and humans became 
possible [6, 7], several research groups including the Giessen group attempted clinical islet 
transplantation in the patients in 1980s–1990s [8]. Although early clinical experience had 
been unsuccessful with only some of the recipients being insulin-independent for a short 
while, other procedures such as organ preservation, islet isolation, and immunosuppres-
sive regimen had been steadily improved [9, 10]. In 2000, Shapiro et al. reported a seminal 
paper in the New England Journal of Medicine and demonstrated that islet transplantation 
could lead to insulin-independence at least for a year in all seven type 1 diabetes (T1D) 
patients [11]. Since then, an international collaborative team reproduced this result from the 
clinical trials involving more patients from various ethnicities and continents [12]. Hering 
et al. very recently published an important result from a Phase 3 clinical trial, which had 
intended to test the efficacy and safety of the standardized human pancreatic islet product 
in the patients with impaired awareness of hypoglycemia (IAH) and severe hypoglycemic 
events (SHEs). The results showed that islet transplantation was effective for preventing 
hypoglycemic unawareness and providing sustained glycemic control (<5.6% of HbA1c) 
and thus should be considered for patients with T1D and IAH in whom other less-invasive 
treatments have been ineffective in preventing SHEs [13]. Although human allogeneic islet 
transplantation is now considered to be widely applicable to more T1D patients possibly 
under the coverage of health insurance reimbursement, the supply of donor organ is sig-
nificantly limited, leading to only 0.1% of the patients gaining access to this promising 
therapy.
Porcine islets have long been considered to be the best alternative source for the human 
counterpart [14]. Pigs are easy to breed and have large litters at delivery and, most impor-
tantly, have high degree of physiological similarity to humans and a long history of use of 
porcine insulin for treating T1D patients. In addition, they can be bred in specific patho-
gen-free (SPF) and/or designated pathogen-free (DPF) status and thus healthier donor 
pancreata can be supplied unlimitedly, though relatively high cost is required for main-
taining them in a clean facility which is regularly monitored for microbial pathogens. To 
achieve clinical xenotransplantation, several groups started pig-to-NHP islet xenotrans-
plantation from the late 1990s [15]. However, in these early studies, porcine islets that had 
been transplanted into the portal vein or kidney subcapsule of the monkeys survived only 
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for several days to weeks despite of using strong immunosuppression regimen. Loss of the 
significant number of islets  immediately after transplantation has been the most difficult 
obstacle to overcome. Goto et al. had focused on this phenomenon and tried to delineate 
the cellular and molecular mechanism underlying this early islet loss [16]. Indeed, they 
coined the term instant blood-mediated inflammatory reaction (IBMIR), and this problem 
still remains a significant barrier for long-term survival of porcine islet in the monkeys 
as well as in allogeneic and even in autologous islet transplantation settings [17, 18]. In 
2006, two independent groups first succeeded in prolonging the survival of porcine islets 
(adult porcine islets and neonatal porcine islets) for longer than 3 months, using anti-
CD154 monoclonal antibody-based immunosuppression [19, 20]. Since then, the survival 
duration of the porcine islet graft in the monkeys has been lingering around one year at 
most in a very limited number of the recipients, even though multiple genetically modified 
pigs were used [21]. In 2009, International Xenotransplantation Association (IXA) released 
a consensus statement on conditions for undertaking clinical trials of porcine islet prod-
ucts in T1D [22] and recently updated this document [23]. To justify clinical xenotrans-
plantation, prerequisite results that should be obtained in preclinical NHP studies were to 
show the maintenance of fasting blood glucose levels (BGLs) of <150 mg/dL and nonfast-
ing levels of <200 mg/dL in the absence of exogenous insulin or in the presence of greatly 
reduced insulin requirements in at least five out of eight consecutive NHPs (now four out 
of six consecutive NHPs in an updated version). Follow-up should be for a period of at 
least 6 months in all cases and ideally for 12 months in one or two successful cases [24, 25]. 
Recently, our group reported successful results where five consecutive diabetic monkeys 
achieved normoglycemia for at least 6 months after transplantation of adult porcine islets, 
with the longest survival day reaching to >603 days [26]. During a follow-up study, one 
monkey showed normoglycemia up to ~1000 days using a CD40-CD154 blockade such as 
anti-CD154 or anti-CD40 monoclonal antibody [27]. These two studies pose an important 
implication that porcine islet graft can survive in the liver, which is rather a harsh environ-
ment, for a significantly long duration. The caveat of these studies would be transplanting 
relatively high numbers of islets (100,000 IEQ/kg) to maintain normoglycemia for a long 
duration, which would reflect the species incompatibility between NHP and pig. The nor-
mal fasting blood glucose level (BGL) of a monkey has been known to be around 60 mg/
dL, and the monkey requires higher amount of insulin for glycemic control than pigs and 
probably humans [28]. As rhesus monkeys have about 25-year lifespan, 1000 days could 
approximate to 3000 days (>8 years) in humans, suggesting that transplanted porcine islets 
can treat diabetic patients for a long time, given that immunosuppression should be well 
maintained with suitable drugs. Currently, our group is actively seeking to develop clini-
cally applicable immunosuppressive regimen in the same pig-to-NHP islet xenotransplan-
tation model.
In this chapter, we will describe the detailed procedures of islet isolation from adult SNU 
miniature pigs, diabetes induction and islet transplantation, immune monitoring after trans-
plantation, and finally biopsy and subsequent immunohistochemical analyses. Because other 
related topics including encapsulated pig islets, islet sources, immunosuppression regimen, 
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and overall results from several pig-to-NHP islet xenotransplantation have been elegantly 
described elsewhere [15, 29–32], here we will focus on the above themes while briefly review-
ing past and current status of each area.
2. Porcine islet isolation DPF SNU miniature pigs
2.1. History and characteristics of SNU miniature pigs
Islets for transplantation can be obtained from adult, neonatal, fetal, and embryonic pigs. 
There is still a debate on the best source of the porcine islets, but at least adult, neonatal, and 
embryonic pancreata have been shown to be efficient for controlling hyperglycemia in higher 
mammals including NHPs [19, 20, 33]. Because advantages and disadvantages of using each 
islet source have been repeatedly discussed elsewhere [30, 34], here we focus on adult porcine 
islets from DPF miniature pigs. Our group had obtained an SPF miniature pig strain from 
the University of Chicago in 2004 and have been breeding and maintaining a closed herd 
in a SPF barrier facility. About 41 viral, 35 bacterial, 2 fungal pathogens, and 25 parasites 
were screened and confirmed negative in microbial examinations that have been performed 
on a regular basis (at least once two years), implying that this closed herd is in DPF status 
[35]. Also, all SNU miniature pigs have been tested for the presence of porcine endogenous 
retrovirus (PERV) via reverse transcription-polymerase chain reaction (RT-PCR). The results 
showed that PERV A, B, and C genotypes were present in the genome. However, reverse tran-
scription activity of PERV assessed by in vitro reverse transcriptase assay in >60 of monkeys 
that underwent porcine islet transplantation was not observed. This observation is supported 
by the gene sequence data of PERV in SNU miniature pig, showing that most of the PERV 
genes were integrated into the chromosome as defective forms such as deletion, insertion, or 
inversion (data not shown).
2.2. Islet yield from SNU miniature pigs
In 2007, we have published the first results of islet isolation from SNU miniature pigs (at that 
time, this pig was named Chicago Medical School [CMS]). In that report, we compared the 
islet yield from 9 adult SNU pigs (>12 months old), 6 young SNU pigs (6–7 months old), 4 
other adult miniature Prestige World Genetics (PWG) pigs (>12 months old), and 13 adult 
market pigs, and found significantly higher yield of islets from adult SNU pigs than the other 
three groups: The yield was ~9600 islet equivalent per 1 g pancreas (IEQ/g), which marked 
the highest value that had ever been reported worldwide [36]. Moreover, we published the 
results based on 68 successful cases of isolation attempts and found several parameters that 
predicted for higher yield of islet isolation in 2009: old age of >2 years, male preference, preg-
nancy experience in female, and good distension of pancreas by collagenase injection [37]. 
Since then, we have preferred to use adult SNU pigs older than 2 years and standardized all 
isolation procedures from pancreas procurement to islet purification (Figure 1). The results of 
islet isolation remained stable during the past 5 years, and the yield was ~6000 IEQ/g pancreas 
and total ~300,000 IEQ/isolation attempt.
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2.3. Quality control of isolated islets from SNU miniature pigs
In order to gain consistent glycemic control after transplantation of porcine islets in NHPs, 
quality control of isolated islets is important. For our pig-to-NHP islet xenotransplan-
tation experiments, we performed three independent assays that included (1) islet cell 
viability test using β-cell specific fluorescent dye Fluozin-3, mitochondrial activity indica-
tor Tetramethylrhodamine, Ethyl Ester (TMRE), and a fluorescence-activated cell sorting 
(FACS) machine, (2) glucose-stimulated insulin secretion (GSIS), and (3) nondiabetic obese 
severe combined immunodeficiency (NOD/SCID) mouse bioassay where four streptozoto-
cin (STZ)-induced diabetic mice were transplanted with 2500 IEQ of porcine islets under the 
kidney subcapsule, and their BGL were monitored 2–3 times per week for at least 2 months 
(Figure 2). Our recent study showed that the isolated porcine islets were >90% pure, con-
tained >80% healthy β-cells, and had >60% diabetes correction capacity, each demonstrated 
by dithizone staining, FACS analysis, and NOD/SCID bioassay, respectively [26]. Although 
the fold increase of insulin upon glucose stimulation of porcine islets overall reached >1, the 
results from GSIS assay were highly variable and did not reflect the potency of the isolated pig 
islets, unlike those from other species (data not shown).
Figure 1. Whole procedure of islet isolation from a DPF SNU miniature pig. (A) A pig transferred to an operating room in 
a cage. (B) The pig was anesthetized with ketamine and xylazine. (C–F) The pig was moved to an operating table using a 
lift, intubated, and kept under anesthesia under isoflurane gas. G; Oxygen saturation was monitored. (H–I) Surgery was 
started under aseptic condition. (J–K) The pancreas was removed, trimmed, and weighed. (L) Collagenase was infused 
into the pancreatic duct in a cold infusion chamber while monitoring the pressure. (M) The pancreas was incubated in 
a Ricordi chamber for 20–25 min. (N) The tissue digest was examined under a microscope before the purification step 
using a COBE2991 processor. (O) Final islet preparation that has been stained with dithizone after purification.
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3. Diabetes induction in monkeys and transplantation procedure via the 
portal vein
3.1. Diabetes induction in monkeys
There are several methods to induce diabetes mellitus (DM) in the monkeys such as total pan-
createctomy [38], partial pancreatectomy (75% resection of the pancreas) followed by low-
dose STZ (15 mg/kg) injection [39], and high-dose STZ (80–150 mg/kg) injection [40]. Pros and 
cons of each DM induction method are summarized in Table 1. STZ is selectively uptaken by 
the glucose transporter 2 (GLUT2), and induce cell death by massive DNA alkylation [41]. 
Because GLUT2 is mainly expressed in the pancreatic β-cell, hepatocytes, and basolateral 
membrane of small intestine and renal tubular cells [42], those organs can be damaged by 
STZ injection. To prevent systemic side effect of STZ, one group suggested that STZ should 
be injected into celiac artery and branches supplying blood to the pancreas after temporary 
embolization of the hepatic and gastric arteries [43]. However, the equipment such as C-arm 
or fluoroscopy and higher degree of technical skill for arterial catheterization is required to 
use this method. Zhu et al. reported an in-depth review article for DM induction in NHPs for 
islet transplantation [44]. Recently, our group published the procedures of STZ-induced DM 
induction and subsequent DM management before and after islet transplantation in rhesus 
monkeys [45].
3.2. Induction of DM using high dose of STZ injection
A central venous catheter (5Fr. Dual-Lumen PICC; Bard Access Systems, Salt Lake City, UT, USA) 
was inserted into the right internal jugular vein in monkeys under general anesthesia. Monkeys 
Figure 2. Quality control of the isolated porcine islets. A portion of the isolated porcine islets was tested for their potency 
using two independent assays as follows: *NOD/SCID bioassay; four mice were rendered diabetic by injecting STZ (200 
mg/kg) and BGLs were followed after porcine islet transplantation (marginal mass; 2500 IEQ) into subcapsular region 
of the kidney. After nephrectomy, hyperglycemia was confirmed, and the harvested kidney was immunostained with 
anti-insulin antibody. FACS index; porcine islets were dissociated into single cells and were stained with Fluozin-3 and 
TMRE for measuring β-cells and mitochondrial potential, respectively. Then, the stained cells were analyzed by FACS. 
FACS index was calculated by Fluozin-3 positive (β-cells) × TMRE positive cell fraction.
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were fasted overnight and were prehydrated with normal saline (NS; 0.9% NaCl, 5 mL/kg/hr intra-
venously [i.v.]) via a tether system for 12 h before STZ (Sigma–Aldrich, St Louis, MO, USA) admin-
istration to reduce adverse nephrotoxic effects. A high dose of STZ (110 mg/kg) was diluted with 10 
mL of normal saline and given i.v. within 10 min at 4 pm to prevent hypoglycemia at 9 am the next 
day. Because maximum nadir of hypoglycemia usually occurs about 17 h after STZ injection, 5% 
dextrose solution was infused at 1 h after STZ injection to prevent hypoglycemia and nephrotoxic-
ity. Intravenous glucose tolerance test (IVGTT) and arginine stimulation test (AST) were conducted 
within 1–2 weeks after STZ injection. For IVGTT, a bolus of glucose solution (0.5 g/kg) was admin-
istered into the right saphenous vein. Two mL of blood was collected from the left saphenous vein 
at baseline, immediately before injection of glucose, 2, 5, 15, 30, 60, 90, and 120 min after injection 
of glucose to measure blood glucose and C-peptide. BGL were measured using a small electrode-
type blood glucose meter (Accu-Chek™, Roche Diagnostics, Seoul, Korea). For AST, 70 mg/kg of 
arginine (Sigma–Aldrich, St Louis, MO, USA) was administered into the right saphenous vein. 
Two mL of blood was collected from the left saphenous vein at baseline, 0, 1, 2, 3, 4, 5, and 10 min 
after administration of arginine to measure C-peptide. Complete DM was confirmed by persistent 
hyperglycemia and <1 ng/mL of fasting C-peptide levels and absence of C-peptide responses in 
IVGTT and AST.
3.3. Exogenous insulin treatment procedure in diabetic monkeys
Because the monkeys require high doses of insulin to sustain normoglycemia and are easily suc-
cumbed to metabolic deteriorations such as ketone body formation if they are not adequately 
treated, insulin treatment is very important to keep animals healthy after STZ injection. Animals 
were fed on commercially available certified primate biscuit diet (2050C, Harlan, Indianapolis, 
IN, USA). Calorie intake was maintained within 70–130 Kcal/kg/day which were divided 
equally at 9 am and 4 pm. After confirming complete DM induction, BGL was checked at least 
two times per day. Desired target value of the fasting BGL was approximately 80–150 mg/dL in 
the diabetic monkeys. To do so, each meal was not fed until the fasting BGL was measured at 9 
am and 4 pm. Intermediate-acting form of insulin (NPH; Novolin N, Green Cross Corp., Yongin, 
Korea) and long-acting form of insulin (glargine; Lantus, Sanofi-Aventis Korea, Seoul, Korea) 
were injected subcutaneously after feeding at 9 am and 4 pm, respectively. Because insulin 
glargine and NPH that had been injected at different time points can influence BGL at the time 
Total pancreatectomy (TP) Partial pancreatectomy (PP) 
+ Low dose STZ injection
High-dose STZ injection
Pros Usage for auto- or alloislet source [81]
Unfailing method of DM induction
Usage for alloislet source
Less invasive compared to TP
Less systemic toxicity compared 
to high-dose STZ injection
Less invasive
More convenient
Low possibility of regeneration 
of β-cell [82]
Cons Invasive
Requires a precise surgical technique
Loss of exocrine function (sometimes 
requirement of oral administration of 
pancreatin and other islet hormones)
High surgical mortality
Increased possibility of 
regeneration of β-cell
More invasive compared to 
high-dose STZ injection
More systemic toxicity 
compared to TP
Instability of STZ in solution
Liver and kidney toxicity
Nausea and vomiting
Table 1. Pros and cons of each diabetes mellitus induction method.
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of subsequent measurement, the algorithm of insulin dose adjustments that have been modified 
from the method used in human clinic [46] was used to maintain target fasting BGL (Table 2).
3.4. Transplantation procedure via the portal vein
There are two popular methods to transplant the islets via the portal vein: one is to infuse the 
islets through a jejunal vein after laparotomy [26]; and the other is to use percutaneous tran-
shepatic portal catheterization guided by ultrasound technology [47]. The latter is less invasive 
than the former, but special equipment—such as ultrasound and C-arm—and the technique 
for ultrasound-guided percutaneous transhepatic portal vein catheterization are indispens-
able. Because of this limitation, most research groups prefer to use the former method in NHP 
study. In our study, the monkeys were fasted for 12 h and a laparotomy was performed. The 
jejunal arch was exposed, and a 22-gauge catheter was inserted through the jejunal vein and 
advanced near the portal vein. The porcine islets were infused under gravity pressure for 8–12 
min (Figure 3). The vessel was ligated with a 5–0 prolene suture, and the tether system was 
applied for continuous fluid therapy and infusion of low-dose glucose, if necessary.
Figure 3. Islet transplantation into the portal vein through a jejunal vein. Porcine islets were resuspended in tissue 
culture media and infused via a jejunal vein of the diabetic rhesus monkey under anesthesia.
Fasting plasma glucose (mg/dL) Insulin dosing
<40 No insulin injection
<60 Reduce by 1–2 U
60–80 Reduce by 0.5 U
80–150 No change
151–250 Increase by 0.5 U
251–350 Increase by 1 U
>350 Increase by 1.5 U
Table 2. Insulin dose adjustments according to the fasting blood glucose levels [45].
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4. Immune monitoring after porcine islet transplantation
4.1. Monitoring of humoral immune responses
Porcine islet transplantation in NHP has been known to elicit humoral responses against 
porcine antigens, including Galα1,3Gal (Gal), and non-Gal antigens [48]. Gal is a carbohy-
drate antigen, which is expressed universally in most species including bacteria and fungi, 
but not in humans and old world NHPs. Anti-Gal is the most abundant form of natural 
antibody in humans (mostly found as IgM, IgG, and IgA isotypes to a lesser extent). CD40 
signaling on B cells, which is acquired through the interaction with CD154 expressed on 
T cells, is critical for the survival and proliferation of B cells, antibody production, isotype 
switching, germinal center formation, memory generation, and production of numerous 
cytokines [49]. Antibodies targeting CD40-CD154 costimulation pathway have been shown 
to efficiently suppress humoral responses including anti-Gal and anti–non-Gal antibodies in 
the recipients [19, 20]. Indeed, immunosuppression regimen including anti-CD154 antibody 
suppressed the induction of anti–non-Gal and anti-Gal antibodies and prolonged islet graft 
survival for up to >603 days in NHP recipients [26]. In contrast, similar immunosuppression 
regimen including anti-CD40 antibody, instead of anti-CD154, suppressed xenoreactive IgG 
responses after islet transplantation as well, but could not sustain the graft function for a 
prolonged period [50]. Therefore, suppression of humoral responses against xenoantigens 
seems to be essential, but not quite enough to sustain graft survival in porcine islet transplan-
tation. In our pig-to-NHP islet xenotransplantation model, monitoring of humoral responses 
after islet transplantation in the recipients is performed as follows: (1) weekly measurement 
of anti-Gal IgG and IgM using an in-house enzyme-linked immunosorbent assay (ELISA), 
(2) measurement of anti-donor pig peripheral blood mononuclear cells (PBMC) IgG and IgM 
using an in-house flow cytometry assay at every 2–3 months interval with the serum samples 
that had been collected weekly and stored in aliquots, and (3) measurement of anti-porcine 
endothelial cells (PEC) IgG every 2–3 months by flow cytometry using weekly collected and 
stored serum aliquots. As a control, the levels of IgG binding to galactosyl transferase knock-
out (GTKO) PECs (kindly provided by Dr. Shuji Miyagawa in Osaka University, Japan) were 
measured in parallel.
The levels of anti-Gal IgG and IgM antibodies are measured by ELISA as follows [50]: each 
well was coated with 100 μL of Galα1,3Gal β1-4GlcNAc-human albumin (5 μg/mL; GlycoTech, 
Gaithersburg, MD, USA) and then blocked with 1% human albumin (Green Cross Corp., 
Yongin, Korea) diluted in phosphate-buffered saline (PBS). Monkey plasma (100 μL) diluted 
1:50 (for anti-Gal IgG) or 1:100 (for anti-Gal IgM) in 0.1% human albumin-supplemented PBS 
was added into each well in duplicate and incubated at 37°C for 30 min. Then, the signal was 
detected with the peroxidase-conjugated anti-human IgG or anti-human IgM (Sigma-Aldrich, 
St. Louis, MO, USA) and subsequent color development. Serial dilutions of the selected lot of 
monkey plasma (as a calibrator) were tested in parallel. A mean absorbance of the sample was 
compared with those of the calibrator and each antibody level of the sample was calculated 
from the calibration curve. High-level and low-level control plasma samples were simultane-
ously tested in each run to validate the performance of assays.
Pig-to-Nonhuman Primate (NHP) Naked Islet Xenotransplantation
http://dx.doi.org/10.5772/intechopen.69001
101
The detection of xenoreactive antibodies binding to porcine cells was performed by flow 
cytometry [51]. Single-cell suspensions (105/tube) of cultured PEC cells or PBMC obtained 
from the donor pigs were mixed with 50 μL of the plasma diluted 1:10 in PBS containing 1% 
human albumin and 30 mM EDTA, and incubated at 4°C for 30 min. The plasma was then 
incubated with FITC-conjugated F(ab)
2
 fragments of a rabbit immunoglobulin specific for 
human IgG or human IgM (DAKO, Glostrup, Denmark) and measured using a FACSCalibur 
(BD Biosciences, San Jose, CA, USA) flow cytometer. The extent of antibody binding was 
expressed as the mean fluorescence intensity (MFI): MFI of the sample subtracted by the MFI 
of the negative control (porcine plasma). To reduce inter-variation, cohort samples obtained 
every week were assayed in duplicate in a single run, and the number of samples in each 
assay did not exceed 20. High-level and low-level control plasma samples were simultane-
ously tested in each run to validate the performance of assays.
4.2. Monitoring of cell-mediated immune responses
Since the current clinical islet transplantation procedure has been performed in the liver through 
the portal vein, IBMIR mediated by diverse nonimmunological and immunological factors is 
known to contribute to early islet loss [52]. Although the exact mechanisms underlying IBMIR 
need to be elucidated further in pig-to-NHP islet transplantation, activation of coagulation cas-
cades together with platelet activation, tissue factor release, and thrombin release is observed dur-
ing IBMIR, and the extent may be stronger than that observed in allogeneic islet transplantation 
[53]. Strong complement activation has been observed during IBMIR [54]. In particular, activa-
tion of alternative complement pathway was profound in pig-to-NHP islet transplantation [55]. 
Following immediate responses by soluble inflammatory mediators, infiltration of islet grafts by 
large numbers of activated CD11b+ neutrophils and macrophage was observed [56]. In turn, the 
degranulation of cytotoxic granules and release of inflammatory cytokines, such as TNF-α and 
IL-6 from neutrophils and macrophages, induce the apoptosis of islets. In this sense, infiltrating 
innate immune cells may strengthen the subsequent adaptive immune responses from T and B 
cells. Among the diverse immune responses against porcine islets, T cell response has been the 
most critical barrier against long-term graft survival [57, 58]. Indeed, many T cell-targeting immu-
nosuppressants have been developed to control T cell–mediated immune responses against 
porcine islets. Particularly, costimulation blockade such as CD40-CD154 and B7-CD28 interac-
tions have been proven to be highly effective for prolonged graft survival [19, 20, 59].
To establish an optimal immunosuppressive regimen and to individualize the immunosup-
pressive therapy, the existence of reliable and predictable immunological tools for monitoring 
immunological status after clinical porcine islet transplantation is necessary. Yet, there are 
only a few reports on predictive immune parameters that can estimate the fate of the graft in 
pig-to-NHP islet transplantation model. Therefore, we will describe our own experience for 
finding the appropriate monitoring methods to oversee the immunological events happening 
during graft rejection. In addition, the role of de novo induced-immunosuppressive CD8+ T 
cells will be discussed for the potential markers for predicting graft rejection.
Enzyme-linked immunosorbent spot (ELISPOT) assay is based on the detection of a cytokine 
(e.g., IFN-γ, IL-4, and IL-2) produced by single cells after stimulation with cognate antigens 
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[60, 61]. The secreted cytokine is detected by specific monoclonal antibodies and revealed by 
the generation of discrete spots, reflecting the number of cytokine-secreting cells. It has been 
widely used in measuring antigen-specific responses in the context of vaccine development 
for infectious diseases [62], cancer [63], and autoimmunity [64]. In the transplantation field, 
it has been also used to examine the presence of donor-specific T cells in the patients. For 
example, following human kidney transplantation, it has been proved useful to screen the 
patients at high risk for acute or chronic graft rejection [65]. Also, an increased number of 
IFN-γ-secreting donor-specific cells were detected by ELISPOT in the patients who expe-
rienced an acute rejection [66]. Standardization and cross-validation of alloreactive IFN-γ 
ELISPOT assay were reported in clinical allotransplantation [67, 68]. However, ELISPOT 
assay is yet to be determined for pig-to-NHP islet xenotransplantation model. Recently, our 
group reported the results of the retrospective IFN-γ ELISPOT assay using a time-series of 
PBMC samples from the monkeys with long-term surviving islet grafts (Figure 4) [69].
Accumulating evidence indicates that immunosuppression after T cell depletion affects CD8+ T 
cell homeostasis in the periphery, resulting in the loss of CD28 expression on some subset of 
T cells. Interestingly, repopulated CD8+CD28– T cells have been shown to have immunosup-
pressive activity and be closely related to the graft survival in some allogeneic transplantation 
[70, 71]. In our pig-to-NHP islet xenotransplantation model, absolute number of CD8+CD28–  
T cell population significantly increased during homeostatic reconstitution of T cell subpopula-
tion [26] in which the monkeys were treated with ATG and  immunosuppressive agents such as 
Figure 4. One representative IFN-γ ELISPOT result. (A) STZ-induced diabetic monkey (R015) was transplanted 
with porcine islets (100,000 IEQ/kg) through a portal vein under immunosuppressive regimen comprised of anti-
thymoglobulin, sirolimus, anti-CD40 antibody (2C10R4), and tacrolimus. Fasting BGL and porcine and monkey C-peptide 
were measured. Grey line: fasting BGL, red bar (bar during normoglycemic period): porcine C-peptide, filled inverted 
triangle (▾): monkey C-peptide, pink bar (bar during hyperglyemic period): exogenous insulin. The values above red 
bar indicate porcine C-peptide, (B) After porcine islet transplantation, PBMCs from the recipient monkey were sampled 
at different time-points and stored. Stored PBMCs (2.5 × 105) were cocultured with 5.0 × 105 splenocytes for 40 h and the 
number of IFN-g producing spots was measured. The number of IFN-γ secreting spots was enumerated and compared 
according to the status of graft functioning. (C) Raw data showing the images of IFN-γ secreting cells as visualized by 
chromogen development.
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rapamycin or methyl-prednisone. These resurged CD8+CD28– T cells were immunosuppressive to 
CD4+ T cell activation and proliferation in vitro, suggesting that these cells are regulatory subsets. 
Importantly, blood glucose levels indicative of function of the transplanted islet were closely asso-
ciated with the ratio of CD8+CD28– T to CD4+ T cells, and the transient hyperglycemia or terminal 
graft loss was observed after CD8+CD28– T/CD4+ T cell ratio dropped below 2.0 approximately. In 
this regard, monitoring immunosuppressive CD8+CD28– T cell population together with CD4+ T 
cells will be helpful for predicting graft function in some allogeneic or xenogeneic transplantation. 
However, it is highly likely that reconstituted CD8+CD28– T cells are heterogeneous in nature and are 
mixed together with regulatory CD8+ T cells and cytotoxic CD8+ T cells. This fact may hinder broad 
application of CD28 as a regulatory CD8+ T cell marker. Further study for the identification of sur-
face or lineage markers which could differentiate regulatory CD8+ T cell subset among CD8+CD28- 
T cells is warranted.
5. Liver biopsy and subsequent immunohistochemical procedure
In organ transplantation, tissue biopsy is the standard way to evaluate graft dysfunction or 
rejection. Recent advances in the development and expansion of antibody application have 
generated more sophisticated and powerful diagnostic methods based on tissue biopsy. 
Since the 1990s, diagnosis and determination of graft rejection through a biopsy have been 
a routine clinical practice in human kidney, heart, and lung transplantation. In kidney 
transplantation, standardization of criteria for renal allograft rejection has been published 
[72]. There were many reports on biopsy-based diagnostic methods for other allograft [73, 
74] as well as xenograft rejection [75]. The infiltration of immune cells including T cells, B 
cells, macrophages, and the deposition of antibody/complement to the graft causing graft 
dysfunction and rejection can be revealed by histological analysis through biopsies. Thus, 
the histology-based results were usually semiquantitatively analyzed and correlated to the 
degree of cell infiltration and antibody/complement deposition [74, 76]. For example, C4d 
deposition was correlated with the presence of donor-specific anti-human leukocyte antigen 
(HLA) antibodies [77–79] and was deemed a specific marker for acute humoral rejection [76]. 
Also, CD68+ and CD3+ cell infiltration in the grafts was highly correlated with the extent of 
cellular rejection in heart transplantation [74]. However, in islet transplantation, posttrans-
plantation monitoring tools to examine the graft site are limited, because the porcine islets 
are engrafted throughout the liver in a scattered pattern. Immune-monitoring with periph-
eral blood after transplantation such as measuring absolute counts of T cells, B cells, neutro-
phils, and NK cells is simple and less invasive, but it is difficult to predict whether the islets 
in situ are attacked by immune cells and antibodies in the liver via observing these immune 
parameters. Particularly, after ATG injection, immune cells such as T cells, B cells, and NK 
cells are depleted and detected in very low numbers in the peripheral blood. In contrast, 
a large number of immune cells were observed in the biopsied liver samples, and in some 
cases, overt graft rejection ensued. Therefore, the histological examination of biopsied liver 
sample would have higher predictive value in determining the status of immune response 
against islet graft.
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In our pig-to-NHP islet xenotransplantation study, scheduled or event biopsy was performed 
as needed (Figure 5). Ordinarily, biopsies of the distal portion of the liver were performed. 
Under general anesthesia, the monkey was placed in the supine position. The abdominal wall 
was incised from the xyphoid process to the umbilicus. The margin of the central lobe of the 
liver was gently grasped and excised about 10 mm distal to the margin (wedge biopsy; 1 × 
1 cm). Hemorrhage from the biopsy site was controlled with electrocautery and absorbable 
hemostat (SURGICEL®, Ethicon Inc.). Routine abdominal wall closure was then performed 
[26]. Finally, biopsied sample was washed three times with PBS and transferred to 4% para-
formaldehyde in PBS for fixation.
Troxell and Lanciault [73] reported practical applications of immunohistochemistry for human 
organ transplantation, and elegantly described all the details of antibody selection for immune 
cells and blood coagulation factors in human tissues. However, when these antibodies are 
used in NHP experiments, antigen-antibody reaction did not work as expected in many cases. 
Thus, many researchers have tried to find the antibodies that are suitable for NHP tissues. In 
2009, Kap et al. reported an important paper entitled “A monoclonal antibody selection for 
immunohistochemical examination of lymphoid tissues from non-human primates [80].” In 
this study, they have tested over 100 antibodies against 69 antigens expressed in tissues from 
the great apes, old world monkeys, and new world monkeys. This report was of great help 
in selecting antibodies for use in pig-to-NHP islet xenotransplantation. Antibodies used to 
determine the distribution of B cell, T cell, and macrophages and deposition of complement, 
antibody, and α-Gal are listed in Table 3.
Figure 5. Procedure of liver biopsy in pig-to-NHP islet xenotransplantation. (A) Marginal liver of left central lobe 
(approximately 1 × 2 cm) is resected. (B) After the resection, the resected surface of liver is electro-cauterized for bleeding 
control. (C) After the electro-cauterization, Surgicel® is applied on it. (D) When anti-coagulant or anti-platelet agents 
are administered in the recipients, overlapping guillotine suture method is used to control bleeding because those 
procedures are not enough for bleeding control.
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In our study, triple immunohistochemical staining was routinely performed because it has an 
advantage: capability of examining multiple cell types in the same tissue section. For example, 
T cells and B cells or T cells and macrophages can be observed simultaneously in the islet graft 
site. As it is not easy to identify the islet if the islet has been destroyed or only a few β-cells remain, 
insulin staining should always be performed at the same time (Figure 6). Biopsy samples from 
Antibody Description Company Host Clonality Clone
Anti-αGal Galactose-α-1,3-galactose Vector 
Laboratories
Fluorescein 
labeled Griffonia 
Simplicifolia Lectin I 
(GSL I) isolectin B4
Insulin Pancreatic β-cell marker DAKO Guinea Pig Polyclonal
Insulin Pancreatic β-cell marker Abcam Guinea Pig Polyclonal
Glucagon Pancreatic alpha cell marker Santacruz Rabbit Polyclonal
CD3 T cell coreceptor DAKO Rabbit Polyclonal UCHT1
CD3 T cell coreceptor Santacruz Mouse Monoclonal A1
CD4 Glycoprotein found on the surface 
of immune cells
Santacruz Mouse Monoclonal 1F6
CD4 Glycoprotein found on the surface 
of immune cells
Abcam Mouse Monoclonal 1F6
CD8 Transmembrane glycoprotein that 
serves as a coreceptor for the T 
cell receptor
Abcam Rabbit Polyclonal
CD20 Activated-glycosylated 
phosphoprotein expressed on the 
surface of all B cells
Thermo Mouse Monoclonal L26
CD20cy Activated-glycosylated 
phosphoprotein expressed on the 
surface of all B cells
DAKO Mouse Monoclonal L26
CD68 Glycoprotein which binds to low 
density lipoprotein. expressed on 
monocytes/macrophages
Thermo Mouse Monoclonal KP1
FOXP3 Specific marker of natural T 
regulatory cells
Abcam Mouse Monoclonal 236A/E7
CD31 Platelet endothelial cell adhesion 
molecule (PECAM-1)
Santacruz Rabbit Polyclonal H300
CD31 Platelet endothelial cell adhesion 
molecule (PECAM-1)
DAKO Mouse Monoclonal JC70A
C4d Complement system activation 
marker
LSBio Mouse Monoclonal
Fibrinogen Glycoprotein that helps in the 
formation of blood clots.
Abcam Rabbit Polyclonal
Table 3. Antibody specification of immunohistochemistry for pig-to-NHP islet xenotransplantation.
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the liver were fixed in 4% paraformaldehyde in PBS and embedded according to the conventional 
paraffin-embedding protocol. Paraffin-embedded tissues were sectioned at 4-μm thickness using 
a microtome. The sections were incubated with primary antibody cocktail designed for each 
combined targets. The sections were subsequently incubated with secondary antibody cocktail 
of anti-rabbit/HRP + anti-mouse/AP polymers. For color development, the slides were incubated 
with blue chromogen (Thermo Scientific, Waltham, MA, USA) for AP and DAB chromogen 
(DAKO, Glostrup, Denmark) for HRP. After the slides were treated with protein block solu-
tion (Thermo Scientific, Waltham, MA, USA), they were incubated with guinea pig anti-insulin 
antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), AP-conjugated goat anti-guinea 
pig secondary antibody (Abcam, Cambridge, UK) and then incubated with red chromogen sub-
strate (Zytomed Systems, Berlin, Germany). After the staining procedure, all slides were dried 
at 60°C and mounted with aqueous mounting medium (Thermo Scientific, Waltham, MA, USA). 
The stained sample was examined by Carl Zeiss Axio Imager A1 microscope, and the images 
were taken with a micrograph with AxioVision software (Carl Zeiss AG, Oberkochen, Germany).
6. Conclusion
Recent advances in preclinical studies in pig-to-NHP naked islet xenotransplantation have 
granted a huge momentum in the endeavor for clinical adoption of porcine islets to over-
come donor organ shortage in islet transplantation as a cure for T1D. Safety concerns related 
to porcine islet transplantation have also been significantly lessened by the fact that no 
infection had been detected in several clinical studies using encapsulated neonatal porcine 
islets and porcine islets cotransplanted with Sertoli cells. Importantly, clinically applicable 
Figure 6. Flow chart for anti-insulin antibody-based triple immunohistochemical staining. (A) Whole procedure of triple 
staining is depicted. (B) One representative result of anti-insulin antibody-based triple staining. These micrographs show 
insulin positive b-cells (red) and other immune cells that are either infiltrated or peripherally located (blue or brown).
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 immunosuppressive regimen without anti-CD154 antibody is now being developed. Our 
detailed procedures of porcine islet isolation from DPF miniature pigs, islet transplantation, 
immune monitoring with peripheral blood after transplantation, and biopsy and subsequent 
immunohistochemistry described in this chapter will help other scientists to expedite clinical 
realization of naked porcine islet transplantation using clinically acceptable immunosuppres-
sion in the near future. Also, a quantum leap in advances on gene editing technique that will 
generate multiple genetically modified pigs or possibly PERV-free pigs within a few months, 
and on generation of interspecies chimera that will provide human organs in the pigs will 
heighten the potential of xenotransplantation.
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